Inactive Instrument

Company Immunomedics, Inc.

Equities

IMMU

US4529071080

Biotechnology & Medical Research

Business Summary

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.

Managers

Managers TitleAgeSince
President 54 20-10-22
Director/Board Member - 20-10-22
Director/Board Member 56 20-10-22

Members of the board

Members of the board TitleAgeSince
President 54 20-10-22
Director/Board Member 56 20-10-22
Director/Board Member - 20-10-22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 231,276,363 225,735,485 ( 97.60 %) 119,621 ( 0.0517 %) 97.60 %

Company contact information

Immunomedics, Inc.

300 The American Road

07950, Morris Plains

+973 605 8200

https://www.immunomedics.com
address Immunomedics, Inc.(IMMU)